
|Articles|May 31, 2012
Bevacizumab improves BCVA and central macular thickness in CSME patients
Multiple injections of bevacizumab improve best-corrected visual acuity (BCVA) and central macular thickness in patients with persistant clinically significant macular oedema (CSME)
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
2026 Nobel Prize in Physiology or Medicine awarded for optogenetics discovery
2
Oku Digital Health launches from Topcon to link eye care, primary care
3
EURETINA 2026: Optogenetic therapy MCO-010 aims to restore vision in advanced macular disease
4
Real-world VOYAGER data on faricimab in nAMD, DME, RVO at EURETINA 2026
5



















